MYRIAD GENETICS INC
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
MYGN$5.67-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations for the Years Ended and
Consolidated Statements of Operations
(in millions, except per share amounts)
| Years Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Revenue | $837.6 | $753.2 | $678.4 |
| Cost of revenue | 252.2 | 236.2 | 202.0 |
| Gross profit | 585.4 | 517.0 | 476.4 |
| Operating expenses: | |||
| Research and development expense | 113.4 | 88.7 | 85.4 |
| Sales and marketing expense | 284.1 | 289.2 | 266.8 |
| General and administrative expense | 275.9 | 283.7 | 247.9 |
| Legal settlements | (21.3) | 112.8 | — |
| Goodwill and long-lived asset impairment charges | 56.8 | — | 16.9 |
| Total operating expenses | 708.9 | 774.4 | 617.0 |
| Operating loss | (123.5) | (257.4) | (140.6) |
| Other income (expense): | |||
| Interest income | 1.7 | 2.5 | 2.6 |
| Interest expense | (2.8) | (2.9) | (3.2) |
| Other | 1.1 | (4.4) | 0.6 |
| Total other expense | — | (4.8) | — |
| Loss before income tax | (123.5) | (262.2) | (140.6) |
| Income tax expense (benefit) | 3.8 | 1.1 | (28.6) |
| Net loss | $(127.3) | $(263.3) | $(112.0) |
| Net loss per share: | |||
| Basic and diluted | $(1.41) | $(3.18) | $(1.39) |
| Weighted average shares outstanding: | |||
| Basic and diluted | 90.6 | 82.8 | 80.6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.